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Association of a Simplified Finnegan Neonatal Abstinence Scoring Tool
With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome
Lori A. Devlin, DO; Janis L. Breeze, MPH; Norma Terrin, PhD; Enrique Gomez Pomar, MD; Henrietta Bada, MD; Loretta P. Finnegan, MD; Kevin E. O’Grady, PhD;
Hendrée E. Jones, PhD; Barry Lester, PhD; JonathanM. Davis, MD
Abstract
IMPORTANCE Observer-rated scales, such as the Finnegan Neonatal Abstinence Scoring Tool
(FNAST), are used to quantify the severity of neonatal abstinence syndrome (NAS) and guide
pharmacologic therapy. The FNAST, a comprehensive 21-item assessment tool, was developed for
research and subsequently integrated into clinical practice; a simpler tool, designed to account for
clinically meaningful outcomes, is urgently needed to standardize assessment.
OBJECTIVES To identify FNAST items independently associated with the decision to use
pharmacologic therapy and to simplify the FNAST while minimizing loss of information for the
treatment decision.
DESIGN, SETTING, AND PARTICIPANTS This multisite cohort study included 424 neonates with
opioid exposure who had a gestational age of at least 36 weeks with follow-up from birth to hospital
discharge in the derivation cohort and 109 neonateswith opioid exposure from theMaternal Opioid
Treatment: Human Experimental Research Study in the validation cohort. Neonates in the derivation
cohort were included in amedical record review at the Universities of Louisville and Kentucky or in a
randomized clinical trial and observational study conducted at Tufts University (2014-2018); the
Maternal Opioid Treatment: Human Experimental Research was conducted from 2005 to 2008.
Data analysis was conducted fromMay 2017 to August 2019.
EXPOSURES Prenatal opioid exposure.
MAINOUTCOMES ANDMEASURES All FNAST items were dichotomized as present or not present,
and logistic regression was used to identify binary items independently associated with
pharmacologic treatment. The final model was validated with an independent cohort of neonates
with opioid exposure.
RESULTS Among 424 neonates (gestational age,36weeks; 217 [51%] female infants), convulsions
were not observed, and high-pitched cry and hyperactive Moro reflex had extremely different
frequencies across cohorts. Therefore, these 3 FNAST itemswere removed from further analysis. The
2 tremor itemswere combined, and 8 of the remaining 17 itemswere independently associatedwith
pharmacologic treatment, with an area under the curve of 0.86 (95% CI, 0.82-0.89) compared with
0.90 (95% CI, 0.87-0.94) for the 21-item FNAST. External validation of the 8 items resulted in an
area under the curve of 0.86 (95% CI, 0.79-0.93). Thresholds of 4 and 5 on the simplified scale
yielded the closest agreement with FNAST thresholds of 8 and 12 (weighted κ = 0.55; 95% CI, 0.48-
0.61).
(continued)
Key Points
Question Can a simplified Finnegan
Neonatal Abstinence Scoring Tool
(FNAST), composed only of
dichotomized items that are
independently associated with the
decision to initiate pharmacologic
therapy, discriminate between infants
who did and did not receive therapy as
effectively as the original FNAST?
Findings In this cohort study of 424
neonates with opioid exposure, the
simplified FNAST discriminated
between neonates who did and did not
receive pharmacologic treatment nearly
as well as the original FNAST.
Meaning Use of a simplified FNAST
may provide an accurate means of
identifying neonatal abstinence
syndrome andmay enhance the clinical
utility of the tool.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE The findings of this study suggest that 8 signs of NASmay be
sufficient to assess whether a neonate meets criteria for pharmacologic therapy. A focus on these
signs could simplify the FNAST tool andmay enhance its clinical utility.
JAMA Network Open. 2020;3(4):e202275. doi:10.1001/jamanetworkopen.2020.2275
Introduction
Themedical and nonmedical use of opioids in the United States has increased significantly during the
last decade.1-4 Opioid use disorder (OUD) during pregnancy increased from 1.5 per 1000 live births
to 6.5 per 1000 live births between 1999 and 2014.5 Antenatal exposure to opioids has led to a 5-fold
rise in the incidence of neonatal abstinence syndrome (NAS) between 2004 and 2014, a number that
continues to increase.6,7 Neonatal abstinence syndrome is a withdrawal syndrome that occurs after
the interruption of the passive transfer of maternal opioids at the time of birth. The diagnosis of NAS
is dependent on the presence of key signs of withdrawal, with severity being highly variable.8,9 Every
neonate exposed to opioids in utero is somewhere along the continuum of withdrawal. While some
neonates have mild signs and normal physiologic functions, others have more severe NAS that
requires pharmacologic treatment to avoid major complications.10 Differences in the expression of
NAS is associated withmany factors, including the type(s) of opioid exposure, coexposure with other
illicit drugs and/or psychotropic medications, genetic and epigenetic variability, the gestational age
and sex of the neonate, breastfeeding, and parental engagement.11-17
Observer-rated scales have been used for more than 40 years to assess the severity of NAS and
guide the initiation and adjustment of pharmacologic therapy.18-21 Differences between raters in the
assessment of NAS have been associated with significant differences in initiation and duration of
pharmacologic therapy, length of hospital stay, and health care utilization.22 The Finnegan Neonatal
Abstinence Scoring Tool (FNAST) is commonly used for the assessment of neonates with NAS.23-25 It
is a screening tool that comprises 21 items, with many items having 2 to 4 subcategories and
weighting for each category, which varies from 1 to 5.18,19 Although differences among raters have
been observed with the use of the FNAST,26,27 these rater differences can beminimized with a
comprehensive educational approach that optimizes and thenmaintains interobserver
reliability.22,26-29 Several tools have been developed to shorten and simplify the FNAST,27,30-33 but
existing studies are limited by small cohorts that lack generalizability, study samples that do not
differentiate between neonates with and without pharmacologic treatment, and a lack of external
validation of the findings.
The goal of this studywas to significantly shorten and simplify the original FNAST by focusing on
signs of withdrawal that prompt clinical intervention. In this article, we address the following
questions. First, is information lost by dichotomizing components of the FNAST and eliminating
weighting? Second, are there large differences among cohorts in how frequently specific signs are
observed? Third, which binary-coded FNAST items are independently associated with the receipt of
pharmacologic therapy?
Methods
Retrospective medical record reviews of consecutive neonates with antenatal opioid exposure were
conducted at the University of Louisville and University of Kentucky for infants born in 2014. In
addition, prospective data were obtained from an 8-site clinical trial that comparedmethadone with
morphine for the treatment of NAS (conducted 2014-2018, led by Tufts University)34 and from a
concurrent observational study of neonates whose parents gave consent for the clinical trial but did
not require treatment or whose parents refused consent for randomization in the clinical trial but
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consented to data collection (eFigure in the Supplement). Included neonates had a gestational age
of at least 36 weeks and had no other significant medical or surgical illness. All sites used the FNAST
for assessment, and nonpharmacologic care was the initial treatment for NAS in this study
population.
Data from an external cohort of neonates enrolled in the Maternal Opioid Treatment: Human
Experimental Research (MOTHER) study (conducted 2005-2008) were used to validate the final
model.26 Of the 131 infants in the original study, 109met inclusion criteria for this analysis (ie,
gestational age36weeks; adequate data on timing of treatment initiation; complete FNAST data
on day of treatment or on day 3 of life if not treated). TheMOTHERNAS (MNS) tool included 28 items
(the FNAST plus 7 additional items). Therefore, data for every FNAST itemwere available at each
assessment in theMOTHER data set. The scores used to initiate pharmacologic therapy in the
MOTHER study were calculated from 19 of the 28MNS items, including 3 that are not on the FNAST.
Each site’s institutional review board approved the study. The deidentified retrospective
medical record review from the Kentucky sites was conducted under a waiver of informed consent,
and informed consent was obtained for patients included in the clinical trial, observational cohort,
and the MOTHER study. This study followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline. Analyses were conducted fromMay 2017 to
August 2019.
The present analysis used a single assessment point for each neonate, ie, the time of the highest
score on the day the neonate initially received pharmacologic therapy for NAS or on day 3 of life if
never treated. The third day was selected for analyzing untreated neonates because it was the
median day when treatment was initiated among neonates who were treated. The criteria for initial
treatment for NAS varied by site and included: 3 consecutive scores of at least 8 or 2 consecutive
scores of at least 12 on the FNAST at the Kentucky sites; 2 consecutive scores of at least 8 or 1 score
of at least 12 on the FNAST for the multisite study; and 2 consecutive scores of at least 9 or 1 score of
at least 13 on the NAS scale for the MOTHER study.
Items on the FNAST with multiple categories were dichotomized as present or absent; if any
sign was recorded, the neonate was coded as having the sign (eg, hyperactive Moro reflex and
markedly hyperactive Moro reflex were both coded as hyperactive Moro reflex). The 2 items related
to tremors were combined to form a single binary item.
Statistical Analysis
Differences among the 3 cohorts in the frequency of each binary itemwere tested using a χ2 test for
proportions. Endorsement of each item across cohorts was also compared using the area under the
curve (AUC). Items that differed by more than 50 percentage points among cohorts and items that
were never observed were excluded from subsequent analyses. Forward stepwise multivariable
logistic regression was used to determine which of the remaining items were independently
associatedwith receipt of pharmacologic therapy, adjusting for cohort. The criteria for stepping items
into themodel and retaining items in themodel were P < .10 and P < .05, respectively. Model
discrimination was evaluated using the AUC. The selected items were validated by calculating the
AUC of a multivariable logistic regression on the validation data set. Thresholds for the new score
were selected to optimize agreement between it and the FNAST in categorizing scores into 3 groups:
low (<8 on FNAST), medium (8 to <12), and high (12).
Statistical analysis was conducted with SAS statistical software version 9.4 (SAS Institute).
Except as stated for model building, statistical significance was set at P < .05, and all tests were
2-tailed.
Results
A total of 424 neonates were included in the primary analysis (mean [SD] birth weight, 3122 [618] g;
217 [51%] female infants). Among 238 treated neonates, the median (interquartile range) time to
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treatment was 3 (2-4) days from birth. The frequency of each item in the FNAST is shown in Table 1.
Generalized convulsions, fever (body temperature38.4 °C), and vomiting (projectile) were not
reported. Many of the items had statistically significant differences in percentage endorsement
across cohorts (eg, sleeps <3 h: Louisville group, 70 [55.1%]; Tufts group, 108 [53.2%]; Kentucky
group, 80 [85.1%]; P < .001; body temperature37.2 °C: Louisville group, 30 [23.6%]; Tufts group,
81 [39.9%]; Kentucky group, 18 [19.1%]; P < .001), but such differences only appeared extreme (ie,
greater than 50 percentage points) in the case of high-pitched crying (Louisville group, 98 [77.2%];
Tufts group, 42 [20.7%]; Kentucky group, 75 [79.8%]; P < .001) and hyperactive Moro reflex
(Louisville group, 36 [28.3%]; Tufts group, 35 [17.2%]; Kentucky group, 64 [68.1%]; P < .001)
(Table 2). These 2 items also had the highest AUCs in models comparing endorsement of the item
among cohorts (crying: 0.79 [95%CI, 0.75-0.83]; Moro reflex: 0.72 [95%CI, 0.62-0.77]). Thus, these
Table 1. Original 21-Item Finnegan Neonatal Abstinence Scoring Tool Frequencies Among 424Neonates
Original item Score No. (%)
High-pitched crying
Excessive 2 187 (44.1)
Continuous 3 28 (6.6)
Sleeps after feeding, h
<3 1 83 (19.6)
<2 2 96 (22.6)
<1 3 79 (18.6)
Moro reflex
Hyperactive 2 127 (30.0)
Markedly hyperactive 3 8 (1.9)
Tremors when disturbed
Mild 1 201 (47.4)
Moderate to severe 2 145 (34.2)
Tremors when undisturbed
Mild 3 88 (20.8)
Moderate to severe 4 58 (13.7)
Increased muscle tone 2 389 (91.8)
Excoriation 1 104 (24.5)
Myoclonic jerks 3 13 (3.1)
Generalized convulsions 5 0
Sweating 1 26 (6.1)
Body temperature, °C
37.2-38.3 1 129 (30.4)
≥38.4 2 0
Yawning >3 times/scoring interval 1 21 (5.0)
Mottling 1 124 (29.2)
Nasal stuffiness 1 59 (13.9)
Sneezing >3 times/scoring interval 1 148 (34.9)
Nasal flaring 2 17 (4.0)
Respiratory rate
>60/min 1 138 (32.6)
>60/min with retractions 2 20 (4.7)
Excessive sucking 1 196 (46.2)
Poor feeding 2 100 (23.6)
Regurgitation 2 76 (17.9)
Projectile vomiting 3 0
Stools
Loose 2 88 (20.8)
Watery 3 16 (3.8)
JAMANetworkOpen | Pediatrics Simplified FNAST and the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome
JAMA Network Open. 2020;3(4):e202275. doi:10.1001/jamanetworkopen.2020.2275 (Reprinted) April 8, 2020 4/11
Downloaded From: https://jamanetwork.com/ on 06/03/2020
2 items as well as generalized convulsions (which were not observed) were excluded from
subsequent model building.
The stepwise regression selected 8 items that were independently associated with receipt of
pharmacologic therapy (sleeps <3 hours after feeding: odds ratio [OR], 3.1; 95% CI, 1.9-5.0; P < .001;
tremors when disturbed: OR, 2.3; 95% CI, 1.3-3.9; P = .003; tremors when undisturbed: OR, 3.5;
95% CI, 2.0-6.2; P < .001; increasedmuscle tone: OR, 10.0; 95% CI, 3.9-26.0; P < .001; body
temperature37.2 °C: OR, 2.1; 95% CI, 1.3-3.5; P = .002; respiratory rate >60/min: OR, 2.6; 95% CI,
1.6-4.1; P < .001; excessive sucking: OR, 2.4; 95% CI, 1.5-3.8; P < .001; poor feeding: OR, 3.0; 95% CI,
1.7-5.3; P < .001; regurgitation: OR, 3.2; 95% CI, 1.7-6.2; P < .001) (Table 3). The AUC for the 8-item
model was 0.86 (95% CI, 0.82-0.89) compared with 0.90 (95% CI, 0.87-0.94) for the 21-item
FNAST. When validated with the cohort from theMOTHER study, themodel had an AUC of 0.86
(95% CI, 0.79-0.93). Comparison of the original and simplified scales is seen in Table 4. For example,
the 3 levels of sleeps after feeding were collapsed into 1 category; similarly, the 2 categories of fever
were collapsed into 1. Thresholds of 4 and 5 on the simplified scale yielded the closest agreement
with FNAST thresholds of 8 and 12, with a weighted κ of 0.55 (95% CI, 0.48-0.61) (Table 5).
Discussion
In this cohort study, a simplified, binary, 8-item FNAST scale was developed to discriminate between
neonateswho did and did not receive pharmacologic therapy based on traditional FNAST parameters
(Table 4; eTable in the Supplement). The items were subsequently validated with an independent
cohort of neonates with opioid exposure. The logistic model with the items on the simplified scale
discriminated nearly as well as themodel that incorporated the original FNAST items (AUC, 0.86
[95% CI, 0.82-0.89] vs 0.90 [95% CI, 0.87-0.94]) despite dichotomizing and eliminating many of
the items. The components of the FNAST identified in this 8-itemmodel performed well despite
variation in the algorithm used to initiate pharmacologic therapy among the cohorts (ie, 2
Table 2. Differences in Percentage Endorsement of Finnegan Neonatal Abstinence Scoring Tool Items
Among 424Neonates
Binary Item
No. (%)
P value
MOTHER
(n = 109),
No. (%)
Louisville
(n = 127)
Tufts
(n = 203)
University of
Kentucky
(n = 94)
High-pitched crying 98 (77.2) 42 (20.7) 75 (79.8) <.001 31 (28.4)
Sleeps <3 h after feeding 70 (55.1) 108 (53.2) 80 (85.1) <.001 82 (75.2)
Hyperactive Moro reflex 36 (28.3) 35 (17.2) 64 (68.1) <.001 42 (38.5)
Tremors when disturbed 119 (93.7) 163 (80.3) 64 (68.1) <.001 85 (78.0)
Tremors when undisturbed 60 (47.2) 67 (33.0) 19 (20.2) <.001 41 (37.6)
Increased muscle tone 120 (94.5) 182 (89.7) 87 (92.6) .28 99 (90.8)
Excoriation 36 (28.3) 48 (23.6) 20 (21.3) .44 21 (19.3)
Myoclonic jerks 5 (3.9) 3 (1.5) 5 (5.3) .16 1 (0.9)
Sweating 8 (6.3) 10 (4.9) 8 (8.5) .49 6 (5.5)
Body temperature ≥37.2 °C 30 (23.6) 81 (39.9) 18 (19.1) <.001 1 (0.9)
Yawning >3 times/scoring interval 4 (3.1) 14 (6.9) 3 (3.2) .21 4 (3.7)
Mottling 55 (43.3) 50 (24.6) 19 (20.2) <.001 13 (11.9)
Nasal stuffiness 25 (19.7) 21 (10.3) 13 (13.8) .06 13 (11.9)
Sneezing >3 times/scoring interval 40 (31.5) 67 (33.0) 41 (43.6) .13 34 (31.2)
Nasal flaring 4 (3.1) 5 (2.5) 8 (8.5) .04 3 (2.8)
Respiratory rate >60/min 57 (44.9) 60 (29.6) 41 (43.6) .007 53 (48.6)
Excessive sucking 72 (56.7) 63 (31.0) 61 (64.9) <.001 29 (26.6)
Poor feeding 33 (26.0) 35 (17.2) 32 (34.0) .005 31 (28.4)
Regurgitation 25 (19.7) 24 (11.8) 27 (28.7) .002 19 (17.4)
Loose or watery stools 32 (25.2) 34 (16.7) 38 (40.4) <.001 28 (25.7)
Abbreviation: MOTHER, Maternal Opioid Treatment:
Human Experimental Research.
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consecutive FNAST scores of8 or 1 of12; 3 consecutive scores8 or 2 of12), and they did not
lose predictive power in an independent validation sample that used a different algorithm (ie, the
MNS) for assessing the need for pharmacologic therapy. The high AUC that we observed in the
validation cohort is evidence of the transportability of the 8-item simplified scale, especially since the
MNS scale differed from the FNAST by including some signs that were not in the FNAST and
excluding others that were.
When the FNAST and simplified FNAST scores were categorized according to treatment cutoffs,
the agreement was only moderate (weighted κ = 0.55; 95% CI, 0.48-0.61). There are 2 cutoffs for
the original FNAST that were predetermined at 8 and 12 points, leaving little room to set the
simplified FNAST thresholds to optimize agreement. In practice, the treatment decision is based on
frequent assessments, not a single score. Because there is no criterion standard, there is currently no
method for determining whether an algorithm based on the original FNAST or the 8-item version
would yield better clinical outcomes.
Themodel did not select some signs because they occurred infrequently or almost always and
hence were not useful in predicting pharmacologic treatment for NAS. Not every item that was
associated with the outcome in univariate analyses made it into the final logistic regression model.
Having a high odds ratio in a univariate analysis does not ensure retention in a multivariable model if
an item is associatedwith other items and/or the confidence interval is wide. Signs that were absent
from the final model may still be clinically important, although they do not have to be checked to
make a treatment decision.
Each item on the original FNAST was weighted and based on clinical observations at the time
the tool was developed. Discerning the degree of expression of several items on the original FNAST
has proven difficult.35 Differences in the assessment of withdrawal severity have been associated
with suboptimal short-term outcomes in neonates with NAS.36 In this study, we evaluated
differences in the scoring of individual items of the FNAST among different cohorts (Table 3) and
Table 3. Logistic Regression Analyses Predicting Pharmacotherapy From the Original and Simplified Finnegan
Neonatal Abstinence Scoring Tool Items Among 424Neonates
Original binary item
Univariate analysisa Simplified model with 8 items a,b
OR (95% CI) P value OR (95% CI) P value
High-pitched crying 4.1 (2.0-8.1) <.001 NA NA
Sleeps <3 h after feeding 3.1 (1.9-5.0) <.001 2.8 (1.6-4.8) <.001
Hyperactive Moro reflex 3.5 (2.0-6.2) <.001 NA NA
Tremors
When disturbed 2.3 (1.3-3.9) .003
4.6 (2.0-10.2) <.001
When undisturbed 5.0 (2.9-8.7) <.001
Increased muscle tone 10.0 (3.9-26.0) <.001 9.1 (3.0-27.8) <.001
Excoriation 2.1 (1.2-3.5) .007 NA NA
Myoclonic jerks 7.1 (0.9-57.4) .07 NA NA
Generalized convulsions NA NA NA NA
Sweating 5.2 (1.5-18.1) .01 NA NA
Body temperature ≥37.2 °C 2.1 (1.3-3.5) .002 1.9 (1.1-3.3) .0318
Yawning >3 times/scoring interval 1.4 (0.5-3.7) .48 NA NA
Mottling 1.4 (0.8-2.3) .19 NA NA
Nasal stuffiness 1.5 (0.8-2.9) .25 NA NA
Sneezing >3 times/scoring interval 1.8 (1.1-2.8) .01 NA NA
Nasal flaring 2.2 (0.7-7.2) .19 NA NA
Respiratory rate >60/min 2.6 (1.6-4.1) <.001 2.0 (1.1-3.4) .01
Excessive sucking 2.4 (1.5-3.8) <.001 2.0 (1.2-3.5) .01
Poor feeding 3.0 (1.7-5.3) <.001 2.7 (1.4-5.3) .004
Regurgitation 3.2 (1.7-6.2) <.001 4.0 (1.8-8.8) <.001
Loose or watery stools 1.5 (0.9-2.5) .13 NA NA
Abbreviations: NA, not applicable; OR, odds ratio.
a All models adjusted for cohort.
b Area under the curve for simplified model was 0.86
(95% CI, 0.82-0.89). Cells marked with NA indicate
that the original binary item was not retained in the
simplified Finnegan Neonatal Abstinence
Scoring Tool.
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Table 4. Original 21-Item and Simplified 8-Item FNAST Scoring
FNAST Simplified FNASTa
Original item Score New item Score
High-pitched crying NA NA
Excessive 2
NA NA
Continuous 3
Sleeps after feeding, h
<1 3
Sleeps <3 h after feeding 1<2 2
<3 1
Moro reflex
Hyperactive 2
NA NA
Markedly hyperactive 3
Tremors when disturbed
Mild 1
Any tremors 1
Moderate to severe 2
Tremors when undisturbed
Mild 3
NA NA
Moderate to severe 4
Increased muscle tone 2 Increased muscle tone 1
Excoriation 1 NA NA
Myoclonic jerks 3 NA NA
Generalized convulsions 5 NA NA
Sweating 1 NA NA
Body temperature, °C
37.2-38.3 1
Body temperature ≥37.2 °C 1
≥38.4 2
Yawning >3 times/scoring interval 1 NA NA
Mottling 1 NA NA
Nasal stuffiness 1 NA NA
Sneezing >3 times/scoring interval 1 NA NA
Nasal flaring 2 NA NA
Respiratory rate
>60/min 1
Respiratory rate >60 min 1
>60/min with retractions 2
Excessive sucking 1 Excessive sucking 1
Poor feeding 2 Poor feeding 1
Regurgitation 2 Regurgitation 1
Projectile vomiting 3 NA NA
Stools NA NA
Loose 2 NA NA
Watery 3 NA NA
Abbreviation: FNAST, Finnegan Neonatal Abstinence
Scoring Tool; NA, not applicable.
a Cells markedwith NA indicate that the original binary
itemwas not retained in the simplified FNAST.
Table 5. Comparison of Cutoffs for Initiation of Pharmacologic Treatment Between the Original 21-Item
and Simplified 8-Item FNAST Scores Among 424Neonates
Original FNAST cutoff
Neonates, No. (%)a
Simplified FNAST cutoff
Total0-3 4 ≥5
0-7 87 (20.5) 13 (3.1) 2 (0.5) 102 (24.1)
8-11 47 (11.1) 58 (13.7) 23 (5.4) 128 (30.2)
≥12 25 (5.9) 41 (9.7) 128 (30.2) 194 (45.8)
Total 159 (37.5) 112 (26.4) 153 (36.1) 424 (100)
Abbreviation: FNAST, Finnegan Neonatal Abstinence
Scoring Tool.
a The weighted κ was 0.55 (95% CI, 0.48-0.61).
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found significant differences in the frequency of some items. Themost marked differences were
noted with high-pitched crying and hyperactive Moro reflex, which were excluded from further
analysis.
Several simplified Finnegan-based scoring tools have been developed.27,30,32,33 The 10-item
simplified Finnegan Neonatal Abstinence Scoring System (sFNAST),33 published in 2017, included 7
of 8 items in the scale proposed in this study (ie, tremors, increased muscle tone, poor sleep,
tachypnea, excessive sucking, poor feeding, and feeding intolerance). This overlap is notable
considering the differences in method for deriving the scores. The sFNAST study focused on
neonates who received treatment, usedmultiple assessments from each patient, selected items
based on correlation with the original FNAST, and did not have enough sites to evaluate
heterogeneity. The present study included large numbers of neonates with and without
pharmacologic treatment, used the highest score on the day treatment was initiated (or day 3 of life
if never treated), selected items to optimize discrimination, excluded itemswithmarked differences
among cohorts, and was validated using an independent cohort.
A 5-itemMNS Short Formwas developed based on the ability to discriminate between neonates
receiving pharmacologic treatment and those whowere not treated.32 TheMNS Short Form shares
3 items with our scale (ie, tremors, increased muscle tone, and tachypnea). One item on the MNS
Short Form (excessive irritability) is not on the original FNAST. Similar to our study, there was a single
score per neonate and the goal was optimization of discrimination. The AUC of the 5-itemMNSwas
0.90, which was close to the AUC of 0.94 for the 19-itemMNS. However, there was no independent
validation sample. Furthermore, because data came from a single clinical trial, site-to-site
homogeneity may have beenmore favorable than it would have been in a sample of unrelated sites.
Our proposed scale overlaps with the Eat, Sleep, and Console (ESC) assessment method.37-39
This method assesses if a neonate with opioid exposure can eat at least 1 ounce (or age appropriate
volume) per feed or breastfeed well, sleep at least 1 hour, and be consoled within 10minutes. While
the ESC approach has gained acceptance at many sites in the United States since the initial quality
improvement study introduced the approach in 2017, the generalizability and safety of the approach
has yet to be demonstrated. Tachypnea, which is a key sign of central nervous system irritability and
autonomic dysfunction, is not assessed with the ESC approach. However, it was retained in our
simplified FNAST, in the sFNAST, and in the 5-itemMNS.
Limitations
There are several limitations in this study. First, datawere retrospective for someof the cohorts and
prospective for others. Next,most binary FNAST itemshad statistically significant differences among
cohorts. The 2 items thatwere eliminatedbecause of pronounced sample differences in percentage
endorsement (ie, high-pitched crying andhyperactiveMoro reflex) could perhaps be reintegrated in
the future, if consistency in assessment canbe achieved.Despite the statistically significant variability
of someof the included items, the simplified score’s ability to discriminate neonateswhowere treated
vs thosewhowere untreated (asmeasuredby theAUC)was very high, even in the validation cohort.
Shorter tools havebeenpublished (ie, the 5-itemMNSand theESC), butwe retained8 itemsbecause
of the trade-off betweenbrevity andpotential loss of generalizability. Further prospective studies that
incorporate nursing and caregiver input are needed to establish clinical utility anddetermine the validity
and reliability of this simplified tool in comparisonwith other tools and approaches.
Conclusions
In this study, the 21-item FNAST was simplified to an 8-item scale that discriminated nearly as well as
the original and was validated with an independent cohort. This shorter assessment tool could
simplify clinical assessment by focusing on components that are relatively consistent across sites. It
is important to prospectively validate this scale, which could be widely used and lead to the
standardization of the clinical approach andmanagement of neonates prenatally exposed to opioids.
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